immunoglobulin mu DNA binding protein 2Genealiases: CATF1 · CMT2S · HCSA · HMN6 · HMNR1 · SMARD1
Q-omics provides the consensus-scored IGHMBP2 profile across patient tissues and cancer cell-line models. IGHMBP2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IGHMBP2 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, IGHMBP2 RNA expression shows 19,413 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where IGHMBP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHMBP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHMBP2 survival associations across molecular data types. IGHMBP2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHMBP2 RNA expression–survival associations across cancer types. High IGHMBP2 expression shows unfavorable associations in KIRC, ACC, KICH, LIHC and COAD, but favorable associations in UVM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for IGHMBP2 RNA expression.
This table summarizes IGHMBP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IGHMBP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHMBP2 shows higher tumor expression in HNSC, LIHC, STAD, KIRC, LUSC and KIRP. The HNSC box plot shows higher IGHMBP2 RNA expression in tumor versus normal tissue (log2 FC = +0.735, t-test p < 0.001).
This table shows molecular features associated with IGHMBP2 in patient tissues and cancer cell lines. In patient samples, IGHMBP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, IGHMBP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
